Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study

Gynecologic Oncology

Volumn 101, Issue 1, 2006, Pages 114-119

  Mäenpää, Johanna U ^a   Grénman, Seija E ^b   Jalkanen, Jyrki T ^b   Kuoppala, Tapio A ^b   Leminen, Arto O ^b   Puistola, Ulla S ^b   Vuolo Merilä, Päivi M ^b   Yliskoski, Merja H ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

Carboplatin; First line treatment; Gemcitabine; Ovarian cancer; Paclitaxel; Sequential chemotherapy

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DEXAMETHASONE; GEMCITABINE; METHYLPREDNISOLONE; PACLITAXEL; PROMETHAZINE; RANITIDINE; TROPISETRON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COURSE EVALUATION; CYSTADENOCARCINOMA; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENDOMETRIOID CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LAPAROTOMY; LUNG DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 33644559686     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.043     Document Type: Conference Paper

References (18)

1. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
2. M.J. Piccart, K. Bertelsen, K. James, and J. Cassidy Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 2000 699 708
3. J.P. Neijt, S.A. Engelholm, M.K. Tuxen, and P.G. Sorensen Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J. Clin. Oncol. 18 2000 3084 3092
4. A. du Bois, H. Lück, W. Meier, and H.-P. Adams A randomized clinical trial of cisplatin/paclitaxel vs. carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1329
5. P.A. Vasey, G.C. Jayson, and A. Gordon Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J. Natl. Cancer Inst. 96 2004 1682 1691
6. S.W. Hansen, H. Anderson, and K. Boman Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO Stages IIB-IV (Abstract) Proc. Am. Soc. Clin. Oncol. 18 1999 1379a
7. F.M. Muggia, P.S. Braly, and M.F. Brady Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 18 2000 106 115
8. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, and L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergoup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 1001 1007
9. M. Markman, P.Y. Liu, S. Wilczynski, B. Monk, L.J. Copeland, and R.D. Alvarez Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial J. Clin. Oncol. 21 2003 2460 2465
10. G. Bonadonna, M. Zambetti, and P. Valagussa Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results JAMA 273 1995 542 547
11. S.C. Righetti, G. Della Torre, and S. Pilotti A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res. 56 1996 689 693
12. A.F. Wahl, K.L. Donaldson, C. Fairchild, F.Y. Lee, D.S.A. Foster, and G. Demers Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis Nat. Med. 2 1996 72 79
13. C. Lavarino, S. Pilotti, and M. Oggionni p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma J. Clin. Oncol. 18 2000 3936 3945
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J. Natl. Cancer Inst. 92 2000 205 216
15. G.J. Rustin, A.E. Nelstorp, P. McClean, M.F. Brady, W.P. McGuire, and J. Hoskins Defining response of ovarian cancer to initial chemotherapy according to S-CA 125 J. Clin. Oncol. 14 1996 1545 1551
16. G.J. Rustin, A.E. Nelstorp, M.K. Tuxen, and H.E. Lambert Defining progression of ovarian cancer during follow-up according to CA 125: a North Thames Ovary Group Study Ann. Oncol. 7 1996 361 364
17. A.H. Calvert, and M.J. Egorin Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies Eur. J. Cancer 38 2002 11 16
18. O. Mogensen Prognostic value of CA 125 in advanced ovarian cancer Gynecol. Oncol. 44 1992 207 212